Modality
ERT
MOA
SGLT2i
Target
FcRn
Pathway
Epigenetic
LN
Development Pipeline
Preclinical
~Jul 2022
→ ~Oct 2023
Phase 1
Jan 2024
→ Feb 2030
Phase 1Current
NCT04348062
622 pts·LN
2024-06→2030-02·Terminated
NCT06007171
2,942 pts·LN
2024-01→TBD·Terminated
3,564 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-02-153.9y awayPh2 Data· LN
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1/2
Termina…
P1/2
Termina…
Catalysts
Ph2 Data
2030-02-15 · 3.9y away
LN
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04348062 | Phase 1/2 | LN | Terminated | 622 | HAM-D |
| NCT06007171 | Phase 1/2 | LN | Terminated | 2942 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |